

Index

A

- Acute liver failure (ALF), viral hepatitis, 7
- Adalimab, hepatitis B management in
 - immunosuppression patients, 279
- Alemtuzumab, hepatitis B management in
 - immunosuppression patients, 280
- ALF. *See* Acute liver failure
- Antisense RNA
 - hepatitis D management, 350
 - hepatitis viruses, 267
- APOBEC
 - covalently closed circular DNA deamination, 38, 86
 - recruitment, 92
 - therapeutic targeting, 266–267
 - woodchuck, 196
- Apoptosis, HBx effects, 119–120
- AuAg. *See* Australian antigen
- Australian antigen (AuAg), discovery, 4–5, 14

B

- Bat hepatitis virus (BtHV), zoonotic infection, 47, 53
- B-cell, hepatitis B virus immune response, 146
- BtHV. *See* Bat hepatitis virus

C

- Calcium flux, HBx effects, 119
- cccDNA. *See* Covalently closed circular DNA
- Cell cycle, HBx effects, 120
- Chimpanzee model, hepatitis B virus infection
 - blood test development, 211–212
 - chronic infection, 211
 - historical perspective, 209–212
 - immune response
 - clearance mechanisms, 214–220
 - innate immunity, 213
 - persistence mechanisms, 215, 218
 - prospects for study, 220
 - inoculum size and outcomes, 218
 - vaccine development, 212–213
- Cirrhosis
 - hepatitis B association, 18–19
 - hepatitis D management in decompensated cirrhosis patients, 348
- Core proteins, hepatitis B virus
 - capsid assembly, 92–93, 98–99, 101–102
 - properties, 97

Covalently closed circular DNA (cccDNA)

- animal model studies, 35–36, 38
 - deamination, 38, 86
 - eradication, 1, 9
 - formation, 75–77
 - functions, 91
 - HBx interactions, 117–118
 - host evasion, 142
 - mouse hepatitis B virus infection, 231
 - persistence, 9, 142
 - therapeutic targeting, 85–86, 266–267
- ## Cyclin-dependent kinases
- HBx effects, 120
 - hepatitis B virus assembly role, 93

D

- Dane particle, 97
- DDB1, HBx interactions, 120–121, 267
- Delta antigen. *See* Hepatitis D virus
- Delta hepatitis. *See* Hepatitis D virus
- DNA methyltransferase, upregulation by HBx, 117
- Duck hepatitis B virus. *See* Hepatitis B virus

C

- Endosomal sorting complex (ESCRT), hepatitis B virus
 - particle transport and release, 95–97
- ESCRT. *See* Endosomal sorting complex
- Etanercept, hepatitis B management in immunosuppression patients, 279

F

- Fas, HBx effects, 119

G

- Glomerulonephritis, hepatitis B association, 22
- Gorilla hepatitis B virus, phylogeny with other hepatitis viruses, 49
- Ground squirrel hepatitis virus. *See* Hepatitis B virus
- Guillain–Barré syndrome, hepatitis B association, 23

H

- HBIG. *See* Hepatitis B immunoglobulin
- HBV. *See* Hepatitis B virus

Index

- HBx. *See* Hepatitis B virus X
- HCC. *See* Hepatocellular carcinoma
- HCV. *See* Hepatitis C virus
- HDV. *See* Hepatitis D virus
- Hepatic decompensation, hepatitis B association, 19
- Hepatitis B immunoglobulin (HBIG)
 - liver transplant patient use, 281
 - passive immunization efficacy, 242–243
- Hepatitis B virus (HBV)
 - animal models
 - antiviral therapy, 38–39
 - chimpanzee. *See* Chimpanzee model, hepatitis B virus infection
 - duck hepatitis B virus, 29–31, 34–35, 37, 81–84
 - ground squirrel hepatitis virus, 29, 31
 - hepatocellular carcinoma, 39, 184–185
 - heron hepatitis B virus, 29
 - historical perspective, 29–31
 - life cycle of virus, 35
 - molecular biology studies
 - reverse transcription and priming, 31–35
 - second-strand DNA synthesis, 34
 - mouse. *See* Mouse model, hepatitis B virus infection
 - protein function elucidation, 36–38
 - transient infection, 37–38
 - woodchuck. *See* Woodchuck hepatitis virus
 - woolly monkey hepatitis B virus, 29
 - capsid assembly
 - allosteric regulation, 101
 - biochemistry, 98–100
 - core protein determinants, 92–93, 98–99
 - kinetics, 100–101
 - nucleic acid synergy, 101–102
 - overview, 92
 - capsid structure, 97–98
 - cell entry
 - multistep process, 67–68
 - overview, 65–66
 - prospects for study, 71–72
 - sodium taurocholate cotransporting polypeptide role, 65, 67–70
 - clinical manifestations of infection
 - acute disease, 15–16
 - chronic disease, 16–18
 - extrahepatic manifestations, 22–23
 - genotype influences on chronic disease course, 162–165
 - HbeAg-negative disease, 17–18
 - HbeAg-positive disease, 17
 - occult infection, 22
 - overview, 7–8
 - coinfection
 - hepatitis C virus, 135
 - hepatitis D virus
 - acute hepatitis D, 329–331
 - chronic disease, 332–333
 - helper-independent infection, 331–332
 - hepatocellular carcinoma studies, 332–333
 - overview, 135–136
 - human immunodeficiency virus, 23, 134–135
 - discovery, 27
 - envelopment and release
 - envelope proteins, 94–95
 - maturation signal, 93
 - subviral particles, 95
 - viral particle transport and release, 95–97
 - epidemiology
 - acute disease, 14
 - chronic disease, 14
 - genotype distributions, 161–162
 - genotype influences, 134
 - global prevalence, 130, 132–133
 - hepatocellular carcinoma, 136
 - high-prevalence populations, 130–131
 - indigenous peoples, 131–132
 - low-prevalence populations, 131
 - mortality, 132
 - overview, 129–130, 159–161
 - genome
 - intergenotypic recombination, 162
 - structure, 28–29, 77, 109, 160
 - geographic distribution of genotypes and subgenotypes, 46
 - history of study, 13–14
 - host susceptibility studies, 70
 - immune response overview, 133–134
 - immune response. *See* Immune response
 - origins and evolution
 - genomic fossils, 46–47
 - genotype and subgenotype roles, 49–50
 - human family tree, 54–55
 - indigenous population implications for origins, 55–58
 - mixed infections and recombination, 50–51
 - most recent common ancestor, 45–46
 - mutation rate, 50, 84
 - prospects for study, 59–60
 - theories of origins
 - bat origin, 53
 - coevolution, 53
 - cospeciation, 53
 - cross-species transmission, 53
 - New World origin, 52
 - outcomes by age, 242
 - prevention strategies, 242–243
 - sequelae of chronic disease. *See also* Cirrhosis; Hepatocellular carcinoma
 - cirrhosis, 18–19
 - hepatic decompensation, 19
 - hepatocellular carcinoma, 19–20, 165–167

- species specificity, 70–71
- surface antigen
 - discovery, 5
 - genotype and variant clinical significance, 167–168
 - prognostic value, 20–21
 - seroclearance, 21–22
 - structure, 94–95
 - vaccine development, 5–6, 28
- surface protein domains in infection, 66–67
- tissue tropism, 71
- transmission, 14–15, 129–130, 242
- treatment
 - cure definitions, 264–265
 - early intervention rationale, 263–264
 - failure
 - management, 261–263
 - resistance, 259–261
 - genotype effects on antiviral therapy
 - interferon therapy, 169–170
 - nucleoside/nucleotide analogs, 170–171
 - overview, 168–169
 - goals and treatment end points, 254
 - HBeAg-negative patients
 - duration of therapy, 258–259
 - on-treatment factors in treatment response
 - prediction, 258
 - outcomes, 256–257
 - pretreatment factors in treatment response
 - prediction, 258
 - HBeAg-positive patients
 - on-treatment factors in treatment response
 - prediction, 257–258
 - outcomes, 256
 - pretreatment factors in treatment response
 - prediction, 257
 - hepatitis C virus coinfection patients, 283–284
 - human immunodeficiency virus coinfection
 - patients, 282–283
 - immunosuppression patients
 - anti-CD20 therapy effects, 280
 - anti-CD52 therapy effects, 280
 - anti-TNF- α therapy effects, 279
 - exacerbation of chronic disease, 278–279
 - immunosuppressants in reactivation, 279
 - prevention and management of reactivation, 280–281
 - indications, 254–256
 - liver transplant patients, 281–282
 - novel drug target identification, 265–269
 - pregnant patients
 - efficacy of antiviral drugs, 277–278
 - infant transmission prevention, 276–277
 - pregnancy effects on virus course, 276
 - safety of antiviral drugs, 277
 - therapeutic targets, 253–254
 - variant effects on antiviral therapy, 171
 - vaccination. *See* Vaccination
 - virion structure, 97–98
- Hepatitis B virus X (HBx)
 - animal model studies of function, 36–37
 - apoptosis effects, 119–120
 - calcium signaling effects, 119
 - cancer studies, 121
 - cell cycle effects, 120
 - covalently closed circular DNA interactions, 117–118
 - DDB1 interactions, 120–121, 267
 - enhancer and promoter interactions, 115–117
 - functional diversity, 121–122
 - hepatocellular carcinoma role, 121, 166, 186
 - innate immunity, 143
 - overview, 109–111
 - prospects for study, 123
 - replication role, 111–112
 - structure, 111–115
- Hepatitis C virus (HCV)
 - discovery, 7
 - epidemiology, 2
 - hepatitis B virus coinfection
 - management, 283–284
 - overview, 135
 - management, 1
 - milestones in research and treatment, 2–3
- Hepatitis D virus (HDV)
 - assembly, 323–324
 - cell entry
 - multistep process, 67–68
 - overview, 65–66
 - prospects for study, 71–72
 - sodium taurocholate cotransporting polypeptide role, 65, 67–70
 - clinical manifestations, 8
 - delta antigen forms, 317, 320–321
 - diagnosis, 306
 - discovery, 6–7, 305
 - epidemiology
 - prevalence, 306–307
 - studies
 - 1980s–1990s, 307–308
 - Europe, 308–311)
 - genome
 - circular conformation and uniqueness, 317–318
 - genotypes, 317
 - types of RNA, 316–317
 - hepatitis B virus coinfection
 - acute hepatitis D, 329–331
 - chronic disease, 332–333
 - helper-independent infection, 331–332
 - hepatocellular carcinoma studies, 332–333
 - overview, 135–136

Index

- Hepatitis D virus (HDV) (*Continued*)
- host susceptibility studies, 70
 - origins and evolution, 46, 58–59
 - pathogenesis, 333–334
 - posttranscriptional RNA editing, 322–323
 - replication, 319, 322
 - ribozymes, 318–320
 - severity of disease, factors affecting, 333
 - species specificity, 70–71
 - surface protein domains in infection, 66–67
 - tissue tropism, 71
 - transmission, 305–306
 - treatment
 - acute disease, 340–341
 - chronic disease, 341–345
 - decompensated cirrhosis patients, 348
 - interferon combination therapy with nucleoside analogs, 345–346
 - novel therapies
 - antisense RNA, 350
 - hepatocyte entry inhibitors, 348–349
 - immunotherapy, 350
 - overview, 348
 - prenylation inhibitors, 350
 - nucleoside analogs, 346–348
 - overview, 339–340
 - prospects, 350
 - thymic humoral factor- γ 2, 348
 - thymosin- α 1, 348
 - virion structure, 315–316
- Hepatitis E virus (HEV), discovery, 7
- Hepatocellular carcinoma (HCC)
- animal models, 39–40
 - hepatitis B
 - association, 19–20
 - DNA integration studies, 182–184
 - epidemiology, 136
 - genomic alterations and oncogenic pathways, 181–182
 - genotypes in risk, 165–166
 - HBx role, 121, 166, 186
 - variants in risk, 166–167
 - hepatitis D virus studies, 332–333
 - immunization in prevention, 247
 - incidence, 290
 - mortality, 179
 - overview, 289–290
 - risk factors, 180–181
 - staging
 - BCLC staging, 291–292
 - CLIP score, 291
 - Okuda system, 291
 - overview, 290–291
 - selection of staging system, 292
 - TNM staging, 291
 - treatment
- advanced disease
 - chemotherapy, 293
 - immunotherapy, 293–294
 - novel therapies, 295
 - oncolytic virus therapy, 294–295
 - standard frontline therapy, 292–293
 - early disease
 - adjuvant therapy after hepatectomy, 297–298
 - liver transplantation, 298
 - locoregional ablative therapy, 298–299
 - surgical resection, 297
 - transarterial embolization with chemotherapy, 295–296
- Hepadnaviridae
- comparison of family members, 46–47
 - phylogenetic tree, 48
- Heron hepatitis B virus. *See* Hepatitis B virus
- HEV. *See* Hepatitis E virus
- Hippocrates, hepatitis studies, 3
- Historical perspective, viral hepatitis
- Australian antigen discovery, 4–5
 - early characterization, 3–4
 - screening tools, 5
 - vaccination and treatment, 5–6
- HIV. *See* Human immunodeficiency virus
- Human immunodeficiency virus (HIV), hepatitis B virus coinfection
- management, 282–283
 - overview, 23, 134–135
- ## I
- Immune response
- chimpanzee hepatitis B virus infection
 - clearance mechanisms, 214–220
 - innate immunity, 213
 - persistence mechanisms, 215, 218
 - prospects for study, 220
 - hepatitis B virus
 - adaptive immunity
 - B-cells, 146
 - regulatory T cells, 148
 - T-cells, 146–148
 - Th17 cells, 148
 - Th22 cells, 148
 - antigen immunomodulation, 148–149
 - innate immunity, 142–143
 - mouse hepatitis B virus infection
 - acute hepatitis, 231–234
 - chronic hepatitis, 234–236
 - natural killer cells, 145–146
 - natural killer T cells, 145–146
 - overview, 141–142
 - replication control, 143–144
 - therapies, 149–152
 - vaccination, 150–151

- hepatitis D virus, 334
- woodchuck hepatitis virus
 - cloning and characterization of components in woodchuck, 192–196
 - T-cell response, 196
- Immunization. *See* Vaccination
- Immunosuppression patients with hepatitis B
 - anti-CD20 therapy effects, 280
 - anti-CD52 therapy effects, 280
 - anti-TNF- α therapy effects, 279
 - exacerbation of chronic disease, 278–279
 - immunosuppressants in reactivation, 279
 - prevention and management of reactivation, 280–281
- Infliximab, hepatitis B management in immunosuppression patients, 279
- Interferon
 - chimpanzee hepatitis B virus infection immune response, 215, 220
 - hepatitis B virus
 - genotype effect on therapy, 169–170
 - immune response, 142–144
 - treatment outcomes, 256–257
 - hepatitis C virus management, 1
 - hepatitis D management
 - acute disease, 340–341
 - chronic disease, 341–345
 - combination therapy with nucleoside analogs, 345–346
 - history of hepatitis management, 6
 - hepatitis D virus, 324
 - hepatocellular carcinoma role, 39
- L**
- Lamivudine, liver transplant patient use, 281–282
- Liver cancer. *See* Hepatocellular carcinoma
- Liver transplantation
 - hepatitis B management in recipients, 281–282
 - hepatocellular carcinoma treatment, 298
- Lonafarnib, hepatitis D management, 350
- M**
- Minus-strand, synthesis, 79
- Mouse model, hepatitis B virus infection
 - acute hepatitis, 231–234
 - chronic hepatitis, 234–236
 - historical perspective and types, 229–231
- N**
- Natural killer (NK) cell, hepatitis B virus immune response, 145–146
- Natural killer T (NKT) cell, hepatitis B virus immune response, 145–146
- NF- κ B. *See* Nuclear factor- κ B
- Nivolumab, hepatocellular carcinoma management, 293
- NK cell. *See* Natural killer cell
- NKT cell. *See* Natural killer T cell
- NTCP. *See* Sodium taurocholate cotransporting polypeptide
- Nuclear factor- κ B (NF- κ B), HBx effects, 119–120
- O**
- Ofatumumab, hepatitis B management in immunosuppression patients, 280
- P**
- PAN. *See* Polyarteritis nodosa
- PD-1, therapeutic targeting in hepatocellular carcinoma, 293
- Pembrolizumab, hepatocellular carcinoma management, 293
- Pexa-Vec, hepatocellular carcinoma management, 294–295
- pgRNA. *See* Pregenomic RNA
- Pidilizumab, hepatocellular carcinoma management, 293
- PKA. *See* Protein kinase A
- PKC. *See* Protein kinase C
- Plus-strand. *See* Second-strand DNA synthesis
- Polyarteritis nodosa (PAN), hepatitis B association, 22
- PreCore, animal model studies of function, 36–37
- Pregenomic RNA (pgRNA)
 - digestion, 91
 - ϵ RNA requirement in packaging and protein priming, 82
 - packaging, 78–79
- Pregnancy, hepatitis B
 - efficacy of antiviral drugs, 277–278
 - infant transmission prevention, 276–277
 - pregnancy effects on virus course, 276
 - safety of antiviral drugs, 277
- Pre-S, hepatocellular carcinoma mutations, 167, 181
- Protein kinase A (PKA), hepatitis B virus assembly role, 93
- Protein kinase C (PKC), hepatitis B virus assembly role, 93
- R**
- Replication complex, assembly, 78–79
- Reverse transcription
 - animal studies
 - model, 34–35
 - overview, 31
 - priming, 32–34
 - ϵ RNA requirement in packaging and protein priming, 82

Index

- Reverse transcription (*Continued*)
 genome variability role, 84
 host factors in replication, 82–83
 reverse transcriptase
 human and duck hepatitis B virus comparison,
 83–84
 structure and function, 81–82
 therapeutic targeting, 84–86
- Ribavirin
 hepatitis C management, 1
 hepatitis D management, 346–347
- Ribonuclease H, pregenomic RNA digestion, 91
- Rituximab, hepatitis B management
 in immunosuppression patients, 280
- RNA interference. *See* Antisense RNA
- S**
- Second-strand DNA synthesis
 animal studies, 34
 priming, 80
- Small interfering RNA. *See* Antisense RNA
- Sodium taurocholate cotransporting polypeptide
 (NTCP)
 hepatitis B/D cell entry role, 65, 67–70
 therapeutic targeting, 265–266, 268–269, 349
- SRPK, hepatitis B virus assembly role, 93
- T**
- TACE. *See* Transarterial embolization with
 chemotherapy
- T-cell
 chimpanzee hepatitis B virus infection immune
 response, 215, 217–220
 hepatitis B virus immune response
 CD4 and CD8 T-cells, 146–148
 regulatory T cells, 148
 Th17 cells, 148
 Th22 cells, 148
 hepatitis D virus response, 334
 mouse hepatitis B virus response, 233–235
 therapeutic targeting, 268
 woodchuck hepatitis virus
 immune response, 196
 vaccines, 197
- Telomelysin, hepatocellular carcinoma
 management, 295
- Telomerase reverse transcriptase (TERT),
 hepatocellular carcinoma mutations,
 181–182
- TERT. *See* Telomerase reverse transcriptase
- TGF- β . *See* Transforming growth factor- β
- Thymic humoral factor- γ 2, hepatitis D
 management, 348
- Thymosin- α 1, hepatitis D management, 348
- TLRs. *See* Toll-like receptors
- TNF- α . *See* Tumor necrosis factor- α
- Toll-like receptors (TLRs)
 therapeutic targeting
 hepatitis B, 268
 hepatitis D, 350
 woodchucks, 194
- Transarterial embolization with chemotherapy (TACE),
 hepatocellular carcinoma management,
 295–296
- Transforming growth factor- β (TGF- β),
 hepatitis B virus immune response,
 144–145
- Tumor necrosis factor- α (TNF- α), HBx effects, 119
- V**
- Vaccination
 hepatitis B virus
 barriers
 compliance, 247–248
 infant protection duration, 248–249
 resources, 247
 vaccine failure, 249
 chimpanzee hepatitis B virus infection immune
 response, 212–213
 combination of passive and active immunization,
 244–245
 development, 243
 global view, 245–246
 immune response, 150–151
 passive immunization with HBIG, 242–243
 prevention efficacy
 active immunization, 243–244
 hepatocellular carcinoma, 247
 passive immunization with recombinant
 vaccine, 245
 universal immunization, 246–247
 surface antigen, 5–6, 28
 universal mass immunization program, 245
 woodchuck hepatitis virus
 combination therapy studies, 199
 recombinant viral vector immunization,
 197–199
 T-cell vaccines, 197
- W**
- WHO. *See* World Health Organization
- WHV. *See* Woodchuck hepatitis virus
- Woodchuck hepatitis virus (WHV)
 hepatocellular carcinoma studies, 184–185
 history of study, 29–30, 191
 immune response
 cloning and characterization of components in
 woodchuck, 192–196

- T-cell response, 196
 - persistence, 85
 - replication studies, 34
 - species specificity, 192
 - therapy studies
 - combination therapy studies, 199
 - overview, 196–197
 - prospects for study, 199–202
 - recombinant viral vector immunization, 197–199
 - T-cell vaccines, 197
 - X role, 37
 - Woolly monkey hepatitis B virus. *See* Hepatitis B virus
 - World Health Organization (WHO), Global Hepatitis Programme, 136–138
- X**
- X. *See* Hepatitis B virus X

This is a free sample of content from The Hepatitis B and Delta Viruses.
[Click here](#) for more information on how to buy the book.